Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa

Journal of Infection and Chemotherapy

Volumn 18, Issue 1, 2012, Pages 127-129

  Yamagishi, Yuka ^a   Terada, Michinori ^a   Ohki, Emiko ^a   Miura, Yoko ^a   Umemura, Takumi ^a   Mikamo, Hiroshige ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Breakpoint; Pharmacokinetics pharmacodynamics (PK PD); Piperacillin tazobactam; Pseudomonas aeruginosa

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BROTH DILUTION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INFECTION CONTROL; JAPANESE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

EID: 84863443460     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0285-3     Document Type: Article

References (16)

1. Albrecht SJ, Fishman NO, Kitchen J, Nachamkin I, Bilker WB, Hoegg C, et al. Reemergence of gram-negative health careassociated bloodstream infections. Arch Intern Med. 2006;166: 1289-94. (Pubitemid 43967580)
2. Lautenbach E, Polk RE. Resistant gram-negative bacilli: a neglected healthcare crisis? Am J Health Syst Pharm. 2007;64(Suppl 14):S3-21. quiz S22-S24.
3. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41: 848-54. (Pubitemid 41266753)
4. Vidal F, Mensa J, Almela M, Martinez JA, Marco F, Casals C, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment: analysis of 189 episodes. Arch Intern Med. 1996;156: 2121-6. (Pubitemid 26346971)
5. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005;49:1306-11. (Pubitemid 40463352)
6. MacGowan AP, Wise R. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother. 2001;48(Suppl 1):17-28.
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial testing: seventeenth informational supplement. CLSI document M100-S17. Wayne: Clinical and Laboratory Standards Institute; 2007.
8. Lodise TP Jr., Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother. 2004;48:4718-24. (Pubitemid 39577677)
9. The Committee on Antimicrobial Susceptibility Testing, Japan Society of Chemotherapy. Breakpoints on respiratory tract infections and sepsis. Chemotherapy. 1994;42:905-14.
10. The Committee on Antimicrobial Susceptibility Testing, Japan Society of Chemotherapy. Breakpoints on urinary tract infections. Jpn J Chemother. 1997;45:711-26.
11. The Committee on Antimicrobial Susceptibility Testing, Japan Society of Chemotherapy. Addition of new and existing antimicrobial agents. Jpn J Chemother. 1997;45:757-61.
12. The Committee on Antimicrobial Susceptibility Testing and Clinical Evaluation, Japan Society of Chemotherapy. Breakpoints on respiratory tract infections and sepsis. Addition of new antimicrobial agents. Jpn J Chemother. 2005;53:557-9.
13. The Committee on Antimicrobial Breakpoints, Japan Society of Chemotherapy. Breakpoints on respiratory tract infections, sepsis and urinary tract infections. Addition of new antimicrobial agents. Jpn J Chemother. 2009;57:343-5.
14. Miyazaki S, Morita K, Yamagishi Y, Mikamo H. PK-PD of antiinfectious agents. Tokyo: Unionace; 2010.
15. DeRyke CA, Kuti JL, Nicolau DP. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis. 2007;58: 337-44. (Pubitemid 47017635)
16. Tam VH, Gamez EA, Weston JS, Gerard LN, LaRocco MT, Caeiro JP, et al. Outcome of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008;46:862-7. (Pubitemid 351417187)